CERS Quote, Financials, Valuation and Earnings

Retractable Technologies has a net margin of -17.85% compared to Cerus's net margin of -126.59%. Cerus's return on equity of -35.37% beat Retractable Technologies's return on equity of -26.39%.

Cerus has a consensus price target of $4.67, signalling upside risk potential of 230.97%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Cerus has higher upside potential than Retractable Technologies, analysts believe Cerus is more attractive than Retractable Technologies.

Cerus has a beta of 1.562, which suggesting that the stock is 56.178% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.357, suggesting its more volatile than the S&P 500 by 35.696%.

Cerus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cerus pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Cerus quarterly revenues are $43.2M, which are larger than Retractable Technologies quarterly revenues of $8.3M. Cerus's net income of -$7.7M is higher than Retractable Technologies's net income of -$10.5M. Notably, Cerus's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cerus is 1.42x versus 0.60x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -17.85% compared to Cerus's net margin of -2201.34%. Cerus's return on equity of -35.37% beat VolitionRX's return on equity of --.

Cerus has a consensus price target of $4.67, signalling upside risk potential of 230.97%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 320%. Given that VolitionRX has higher upside potential than Cerus, analysts believe VolitionRX is more attractive than Cerus.

Cerus has a beta of 1.562, which suggesting that the stock is 56.178% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

Cerus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cerus pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Cerus quarterly revenues are $43.2M, which are larger than VolitionRX quarterly revenues of $246.4K. Cerus's net income of -$7.7M is lower than VolitionRX's net income of -$5.4M. Notably, Cerus's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cerus is 1.42x versus 48.25x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -17.85% compared to Cerus's net margin of -2828.67%. Cerus's return on equity of -35.37% beat Catheter Precision's return on equity of -137.84%.

Cerus has a consensus price target of $4.67, signalling upside risk potential of 230.97%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 788.89%. Given that Catheter Precision has higher upside potential than Cerus, analysts believe Catheter Precision is more attractive than Cerus.

Cerus has a beta of 1.562, which suggesting that the stock is 56.178% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.724, suggesting its less volatile than the S&P 500 by 172.434%.

Cerus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cerus pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Cerus quarterly revenues are $43.2M, which are larger than Catheter Precision quarterly revenues of $143K. Cerus's net income of -$7.7M is lower than Catheter Precision's net income of -$4M. Notably, Cerus's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cerus is 1.42x versus 2.58x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -17.85% compared to Cerus's net margin of 0.18%. Cerus's return on equity of -35.37% beat Xtant Medical Holdings's return on equity of -26.62%.

Cerus has a consensus price target of $4.67, signalling upside risk potential of 230.97%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 201.72%. Given that Cerus has higher upside potential than Xtant Medical Holdings, analysts believe Cerus is more attractive than Xtant Medical Holdings.

Cerus has a beta of 1.562, which suggesting that the stock is 56.178% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Cerus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cerus pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Cerus quarterly revenues are $43.2M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. Cerus's net income of -$7.7M is lower than Xtant Medical Holdings's net income of $58K. Notably, Cerus's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cerus is 1.42x versus 0.65x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.